Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KLHDC2 is a substrate-recognition component of the Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, involved in the degradation of proteins ending with specific C-terminal sequences, such as diglycine (Gly-Gly). It plays a crucial role in the ubiquitin-proteasome pathway, particularly through the recognition of C-end degrons in aberrant or truncated proteins. This information is based on the role of KLHDC2 in protein degradation and its involvement in processes like ubiquitination. KLHDC2 acts as part of the DesCEND pathway, targeting proteins with specific C-terminal motifs for degradation. Its role in cancer, particularly in hepatocellular carcinoma, is reflected in its alternative names.
Recognition of C-end degrons leading to ubiquitination and degradation of target proteins
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kelch domain-containing protein 2 (KLHDC2).